Spotlight intensifies on cancer drug reimbursement

Pharmaceutical manufacturers have long been under scrutiny for the methodsthey employ in marketing their products to physicians. Now, increasing concernthat drug makers are winning physician favor by deeply discounting chemotherapymedicines is placing those physicians under the microscopes of federal andstate authorities.

Related Content:

Drug TherapyPractice Management

Urology Times Money Matters: Alternative Investments

What can be learned from CMS data on health care spending?

FDA finalizes blueprint for cancer drug trials involving patients with CNS metastases